What are syndecan‑1 and angiopoietin‑2?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Syndecan-1 and Angiopoietin-2: Biomarkers of Endothelial Dysfunction

Syndecan-1 and angiopoietin-2 are biomarkers of endothelial injury and dysfunction that are released into circulation when the vascular endothelium is damaged, particularly during critical illness, sepsis, and inflammatory states.

Syndecan-1

Syndecan-1 is a membrane-bound proteoglycan that is a key component of the endothelial glycocalyx, the gel-like protective layer covering the vascular lumen that provides antithrombotic, anti-inflammatory, and vascular permeability regulatory functions 1.

Mechanism of Release

  • When the endothelium is injured, the glycocalyx is degraded by inflammatory mediators including heparanase, matrix metalloproteases, reactive oxygen species, hyaluronidase, thrombin, elastase, plasminogen, and cathepsin B 1.
  • Syndecan-1 is shed from the endothelial surface and released into circulation, where elevated levels serve as a marker of glycocalyx damage and endothelial injury 1.

Clinical Significance

  • Elevated syndecan-1 levels are associated with increased mortality in critically ill patients, particularly those with ARDS from SARS-CoV-2 infection (median 15.9 ng/mL in non-survivors vs 12.6 ng/mL in survivors; P = 0.01) 2.
  • Syndecan-1 correlates with ventilatory ratio at baseline (ρ = 0.4; P = 0.001) and day 3 (ρ = 0.5; P < 0.001), indicating association with respiratory dysfunction 2.
  • Higher levels are found in sepsis patients with severe acute kidney injury compared to those without severe AKI 3.
  • Syndecan-1 levels correlate positively with angiopoietin-2 levels both upon admission and at 24 hours after injury in pediatric trauma patients 4.

Important Caveat

  • Syndecan-1 is not endothelium-specific—it is also expressed on epithelial cells and plasmacytes, which limits its specificity as an endothelial marker 1.

Angiopoietin-2

Angiopoietin-2 is an endothelial growth factor stored in Weibel-Palade bodies of endothelial cells and released into circulation during endothelial activation 1.

Mechanism of Action

  • Angiopoietin-2 acts as a competitive antagonist to angiopoietin-1 at their common receptor 1.
  • While angiopoietin-1 promotes anti-inflammatory, anticoagulatory, and anti-apoptotic effects, angiopoietin-2 induces prothrombotic responses by promoting endothelial tissue factor expression and phosphatidylserine exposure in sepsis, leading to disseminated intravascular coagulation 1.
  • Angiopoietin-2 increases endothelial permeability and is considered a critical factor in multiple organ dysfunction 1.

Clinical Significance

  • Angiopoietin-2 is the most robust independent predictor of severe AKI among endothelial biomarkers in sepsis patients with acute respiratory failure (odds ratio 6.07 per log increase, 95% CI 2.34-15.78, P < 0.001) 3.
  • Higher angiopoietin-2 levels are associated with decreased survival in sepsis 1.
  • Elevated levels correlate with hepatic, coagulation, and circulatory failure in sepsis patients 3.
  • Angiopoietin-2 levels are significantly higher in non-pulmonary sepsis compared to pulmonary sepsis 3.
  • In cardiac surgery patients, each 1 ng/mL increase in angiopoietin-2 is associated with a 0.24L increase in extracellular water (P < 0.001) and increased odds of acute kidney injury (OR 1.095,95% CI 1.032-1.169; P = 0.004) 5.
  • Angiopoietin-2 shows strong correlation with extracellular water accumulation over time (r = 0.959, P = 0.041) 5.

Relationship Between Syndecan-1 and Angiopoietin-2

  • Angiopoietin-2 appears to mediate glycocalyx injury, as demonstrated by the strong association between angiopoietin-2 and syndecan-1 levels (correlation coefficient 0.461, P < 0.001) 6.
  • In nephrotic patients, angiopoietin-2 explained 56% of the total observed association between LDL-cholesterol and syndecan-1, suggesting it mediates the relationship between dyslipidemia and glycocalyx derangement 6.
  • Both biomarkers are elevated together in various critical conditions, including pediatric trauma, sepsis, and ARDS 2, 3, 4.

Clinical Utility

Both biomarkers are currently used primarily for research purposes rather than routine clinical diagnosis, as they require specialized laboratory facilities and are not yet part of standard diagnostic criteria for conditions like disseminated intravascular coagulation 1. However, they provide valuable insight into the pathophysiology of endothelial dysfunction in critical illness and may help predict clinical outcomes including mortality, organ failure, and complications.

References

Related Questions

For a 45-year-old Hispanic male weighing 98.4 kg with newly diagnosed type 2 diabetes and normal renal function, currently on 30 U insulin glargine (Lantus) and an insulin-to-carbohydrate ratio of 1 U per 5 g carbohydrate, with post‑meal insulin drip rates of 6, 4, 8, 6 U and overnight fasting drip rates of 2 U each hour, what should the insulin-to-carbohydrate ratio, basal insulin glargine dose, and insulin sensitivity factor be?
In a 65-year-old woman with newly diagnosed diabetes who has been started on metformin and now has an HbA1c of 55 mmol/mol (5.5 %), when should the HbA1c be repeated and the medication reviewed?
In a 70‑year‑old female nursing home resident with finger‑stick blood glucose ranging from 70 to 500 mg/dL who is currently on a sliding‑scale regimen of insulin glargine (Lantus) 12 units when glucose >200 mg/dL and insulin lispro (Humalog) 6 units twice daily when glucose >200 mg/dL, what is the recommended treatment approach?
What is the recommended management for a 70‑year‑old female with diabetes mellitus and chronic liver disease complicated by ascites, portal hypertension with varices, and hepatic encephalopathy?
What preconception management should I, as a diabetologist, provide for a 30-year-old woman with type 2 diabetes mellitus for 3 years, hemoglobin A1c 6.4%, currently taking sitagliptin, metformin, and glimepiride, with a body mass index of 24, who wishes to become pregnant in the next 3–4 months?
Which nonsteroidal anti-inflammatory drug (NSAID) is preferred as first‑line therapy for an otherwise healthy adult?
What are the recommended dosing guidelines for promethazine-dextromethorphan (Promethazine DM) in adults and children?
What is the recommended antibiotic choice and treatment duration for Klebsiella pneumoniae bacteremia in adults?
What is the recommended treatment for a carbapenem‑resistant Escherichia coli infection?
What is the safest antipsychotic medication to use in a patient after a stroke?
What are the recommended dosage and dosing frequency of cotrimoxazole (trimethoprim‑sulfamethoxazole) for adult treatment, PCP prophylaxis, and pediatric patients, including adjustments for renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.